Quotient, CytoAgents develop COVID-19 cytokine storm treatment

By The Science Advisory Board staff writers

April 28, 2020 -- A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials, the companies announced.

The partnership will focus on rapid development of CytoAgents' lead COVID-19 drug candidate, GP1681, for phase I and II trials in 2020. The candidate is a small-molecule inhibitor of cytokine release in activated human immune cells that shows potential in blocking the "cytokine storms" associated with severe illness in COVID-19 cases.

Under the agreement, CytoAgents will use Quotient's formulation and manufacturing expertise to develop and rapidly supply drug product for clinical trials. Quotient will also work to develop a scalable solid oral dosage form for larger patient trials. The program will be conducted at Quotient's specialized drug handling and containment facility in Pennsylvania.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here